Looking forward, the successful clinical translation of this combination strategy will depend on systematic efforts to mitigate these risks.The clinical translation of PARP inhibitor-mediated radiosensitization must carefully navigate its “double-edged sword” effect—enhancing tumor control at the cost of increased normal tissue toxicity (e.g., pulmonary injury, mucositis). This evidence concerns the gene PARP1 and neoplasm.